%0 Journal Article
%A Lahuerta, Juan-José
%A Jiménez-Ubieto, Ana
%A Paiva, Bruno
%A Martínez-López, Joaquín
%A González-Medina, José
%A López-Anglada, Lucía
%A Cedena, María-Teresa
%A Puig, Noemi
%A Oriol, Albert
%A Blanchard, María-Jesús
%A Ríos, Rafael
%A Martin, Jesús
%A Martínez, Rafael
%A Sureda, Anna
%A Hernández, Miguel Teodoro
%A de la Rubia, Javier
%A Krsnik, Isabel
%A Cabañas, Valentín
%A Palomera, Luis
%A Bargay, Joan
%A Mateos, María-Victoria
%A Rosiñol, Laura
%A San Miguel, Jesús F
%A Blade, Joan
%T Role of urine immunofixation in the complete response assessment of MM patients other than light-chain-only disease.
%D 2019
%U http://hdl.handle.net/10668/13863
%X Response criteria for multiple myeloma (MM) require monoclonal protein (M-protein)-negative status on both serum immunofixation electrophoresis (sIFE) and urine (uIFE) immunofixation electrophoresis for classification of complete response (CR). However, uIFE is not always performed for sIFE-negative patients. We analyzed M-protein evaluations from 384 MM patients (excluding those with light-chain-only disease) treated in the GEM2012MENOS65 (NCT01916252) trial to determine the uIFE-positive rate in patients who became sIFE-negative posttreatment and evaluate rates of minimal residual disease (MRD)-negative status and progression-free survival (PFS) among patients achieving CR, CR but without uIFE available (uncertain CR; uCR), or very good partial response (VGPR). Among 107 patients with M-protein exclusively in serum at diagnosis who became sIFE-negative posttreatment and who had uIFE available, the uIFE-positive rate was 0%. Among 161 patients with M-protein in both serum and urine at diagnosis who became sIFE-negative posttreatment, 3 (1.8%) were uIFE positive. Among patients achieving CR vs uCR, there were no significant differences in postconsolidation MRD-negative (
%~